Jil Billy Mamza
YOU?
Author Swipe
View article: Missed opportunities to manage complex comorbidity of heart failure, type 2 diabetes mellitus and chronic kidney disease: a retrospective cohort study
Missed opportunities to manage complex comorbidity of heart failure, type 2 diabetes mellitus and chronic kidney disease: a retrospective cohort study Open
Background Effective management of coexisting heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus (T2D) is critical, yet evidence of adherence to guideline-recommended standards in routine care remains unclear. We…
View article: Inpatient versus outpatient diagnosis of heart failure across the spectrum of ejection fraction: a population cohort study
Inpatient versus outpatient diagnosis of heart failure across the spectrum of ejection fraction: a population cohort study Open
Background Early heart failure (HF) diagnosis is crucial to ensure that optimal guideline-directed medical therapy (GDMT) is administered to reduce morbidity and mortality. Limited access to echocardiography could lead to a later diagnosis…
View article: Patient characteristics and incidence of cardiac amyloidosis: an observational study in the UK clinical setting using electronic health records
Patient characteristics and incidence of cardiac amyloidosis: an observational study in the UK clinical setting using electronic health records Open
Background Cardiac amyloidosis (CA) is associated with a high mortality rate due to sudden or progressive heart failure. It is often misdiagnosed due to non-specific symptoms, and its true incidence and prevalence in the United Kingdom (UK…
View article: Clinical characteristics and treatment patterns of new users of dapagliflozin for heart failure with reduced ejection fraction: an observational study programme across 12 countries (EVOLUTION HF)
Clinical characteristics and treatment patterns of new users of dapagliflozin for heart failure with reduced ejection fraction: an observational study programme across 12 countries (EVOLUTION HF) Open
Background Clinical trials have shown that dapagliflozin, a sodium–glucose cotransporter-2 inhibitor (SGLT-2i), reduces cardiovascular mortality and worsening heart failure (HF). Adoption of new therapies has historically been slow despite…
View article: Identifying subtypes of type 2 diabetes mellitus with machine learning: development, internal validation, prognostic validation and medication burden in linked electronic health records in 420 448 individuals
Identifying subtypes of type 2 diabetes mellitus with machine learning: development, internal validation, prognostic validation and medication burden in linked electronic health records in 420 448 individuals Open
Introduction None of the studies of type 2 diabetes (T2D) subtyping to date have used linked population-level data for incident and prevalent T2D, incorporating a diverse set of variables, explainable methods for cluster characterization, …
View article: Importance of early diagnosis and treatment of heart failure across the spectrum of ejection fraction
Importance of early diagnosis and treatment of heart failure across the spectrum of ejection fraction Open
Introduction Early diagnosis of heart failure (HF) is crucial in ensuring that optimal guideline-directed medical therapy (GDMT) is administered to reduce morbidity and mortality. Limited access to echocardiography could lead to late diagn…
View article: Impact of worsening renal function in patients with incident heart failure across the spectrum of ejection fraction: a population-based longitudinal study
Impact of worsening renal function in patients with incident heart failure across the spectrum of ejection fraction: a population-based longitudinal study Open
Background Renal dysfunction is a common occurrence in patients with heart failure (HF) and may impact on HF treatment and outcomes. HF clinical trial data suggest that worsening renal function (WRF) is associated with worse prognosis, how…
View article: Initiation, titration, and discontinuation - utilization of heart failure medicines in England (EVOLUTION HF UK)
Initiation, titration, and discontinuation - utilization of heart failure medicines in England (EVOLUTION HF UK) Open
Background Guidelines advise early initiation and optimisation of several guideline-recommended pharmacological therapies (GRPTs) for managing heart failure (HF) with reduced ejection fraction. Recent guidelines have expanded this list to …
View article: Risk factors, outcomes and healthcare utilisation in individuals with multimorbidity including heart failure, chronic kidney disease and type 2 diabetes mellitus: a national electronic health record study
Risk factors, outcomes and healthcare utilisation in individuals with multimorbidity including heart failure, chronic kidney disease and type 2 diabetes mellitus: a national electronic health record study Open
Background Heart failure (HF), type 2 diabetes (T2D) and chronic kidney disease (CKD) commonly coexist. We studied characteristics, prognosis and healthcare utilisation of individuals with two of these conditions. Methods We performed a re…
View article: Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19–a data-driven retrospective cohort study
Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19–a data-driven retrospective cohort study Open
Objectives To use national, pre- and post-pandemic electronic health records (EHR) to develop and validate a scenario-based model incorporating baseline mortality risk, infection rate (IR) and relative risk (RR) of death for prediction of …
View article: A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease
A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease Open
Chronic kidney disease (CKD) is associated with increased risk of baseline mortality and severe COVID-19, but analyses across CKD stages, and comorbidities are lacking. In prevalent and incident CKD, we investigated comorbidities, baseline…
View article: Significant reduction in chronic kidney disease progression with sodium‐glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes in a <scp>UK</scp> clinical setting: An observational outcomes study based on international guidelines for kidney disease
Significant reduction in chronic kidney disease progression with sodium‐glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes in a <span>UK</span> clinical setting: An observational outcomes study based on international guidelines for kidney disease Open
Aims To confirm the reno‐protective effects of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors on the onset and progression of chronic kidney disease (CKD) in routine clinical pract…
View article: POS-283 HIERARCHICAL CLUSTERING FOR SUBTYPE DISCOVERY OF INCIDENT CHRONIC KIDNEY DISEASE FROM LARGE LONGITUDINAL ELECTRONIC HEALTH RECORDS
POS-283 HIERARCHICAL CLUSTERING FOR SUBTYPE DISCOVERY OF INCIDENT CHRONIC KIDNEY DISEASE FROM LARGE LONGITUDINAL ELECTRONIC HEALTH RECORDS Open
Chronic kidney disease (CKD) is a leading cause of morbidity and mortality associated with multiple risk factors, complications (in the natural history of cancers and CVD) and various clinical outcomes. Identifying CKD subtypes could help …
View article: Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care
Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care Open
Aim To assess if sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) reduce the risk of all‐cause mortality, cardiovascular death and hospitalization for heart failure (HF) or chronic kidney disease (CKD) to a greater extent than dipeptid…
View article: Variation in availability and use of surgical care for female urinary incontinence: a mixed-methods study
Variation in availability and use of surgical care for female urinary incontinence: a mixed-methods study Open
Background Urinary incontinence affects between 25% and 45% of women. The availability and quality of services is variable and inequitable, but our understanding of the drivers is incomplete. Objectives The objectives of the study were to …
View article: Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473399 individuals
Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473399 individuals Open
Background Lifetime risks of cardiovascular (CV) and renal diseases are high, particularly in type 2 diabetes (T2D), but rarely studied together, and relative disease contributions are unknown. Knowledge of lifetime risk of cardiovascular-…
View article: Lower cardiorenal risk with <scp>sodium‐glucose</scp> cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
Lower cardiorenal risk with <span>sodium‐glucose</span> cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study Open
Aims We compared the new use of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) versus dipeptidyl peptidase‐4 inhibitor (DPP4i) and the risk of cardiorenal disease, heart failure (HF) or chronic kidney disease (CKD), in patients with typ…